目的 探討注射用丹參多酚酸對(duì)急性缺血性腦卒中患者血清中超敏C反應(yīng)蛋白（hs-CRP）、CD62P水平及短期預(yù)后的影響。方法 選取2017年7月—2020年12月保定市第一中心醫(yī)院收治的符合入組標(biāo)準(zhǔn)的急性缺血性腦卒中患者200例為研究對(duì)象，采用隨機(jī)數(shù)字表法分為試驗(yàn)組100例和對(duì)照組100例。對(duì)照組按照指南給予標(biāo)準(zhǔn)化治療，試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上靜脈滴注注射用丹參多酚酸（0.13 g加入0.9%的氯化鈉注射液250 mL），每天1次，兩組均持續(xù)治療14 d，觀察兩組治療前、后血清中hs-CRP以及CD62P水平的變化以及美國(guó)國(guó)立衛(wèi)生研究院腦卒中量表（NIHSS）評(píng)分的變化。結(jié)果 對(duì)照組2例脫落、共98例完成研究，試驗(yàn)組全部完成研究。治療后，兩組NIHSS評(píng)分均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05），且試驗(yàn)組NIHSS評(píng)分明顯低于對(duì)照組（P＜0.05）；治療后，兩組患者血清中hs-CRP、CD62P的水平均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05），且試驗(yàn)組血清中hs-CRP、CD62P的水平顯著低于對(duì)照組（P＜0.05）。結(jié)論 注射用丹參多酚酸可降低炎癥因子（hs-CRP、CD62P）的水平，改善患者的生活質(zhì)量，促進(jìn)患者神經(jīng)功能的恢復(fù)，有利于急性缺血性腦卒中患者的短期預(yù)后，且安全性較高，具有一定的臨床應(yīng)用價(jià)值。

Objective To investigate the effect of Salvianolic Acids for Injection (SAFI) on serum high-sensitivity C-reactive protein (hs-CRP), CD62P levels and short-term prognosis in patients with acute ischemic stroke. Methods A total of 200 patients with acute ischemic stroke who met the inclusion criteria and were admitted to the third department of neurology in the Baoding NO.1 Central Hospital from July 2017 to December 2020 were selected as the research objects. They were divided into the experimental group of 100 cases and the control group of 100 cases by random number table method. Patients in the control group were given standardized treatment according to the guidelines. Patients in the experimental group were given intravenous drip of SAFI, 0.13 g of 0.9% Sodium Chloride Injection 250 mL, once a day, on the basis of the standardized treatment. Both groups were treated continuously for 14 days. The changes of serum high sensitivity C-reactive protein (hs-CRP) and CD62P levels and the changes of the National Institutes of Health Stroke Scale (NIHSS) score before and after treatment in two groups. Results The control group had two cases of detachment, with a total of 98 cases completing the study, and the experimental group all completed the study. After treatment, the NIHSS scores of two groups were significantly decreased, and the difference was statistically significant in the same group before treatment (P＜0.05), and the NIHSS scores of the experimental group were also significantly lower than those of the control group (P＜0.05). The levels of hs-CRP and CD62P in serum were significantly decreased, and the difference was statistically significant in the same group before and after treatment (P＜0.05), and the levels of serum hs-CRP and CD62P in the experimental group were significantly lower than those in the control group (P＜0.05). Conclusions SAFI can reduce the level of inflammatory factors (hsCRP, CD62P), improve the quality of life of patients, promote the recovery of neurological function, and is beneficial to the shortterm prognosis of patients with acute ischemic stroke, certain clinical application value.

R286.1，R971

河北省醫(yī)學(xué)研究重點(diǎn)課題計(jì)劃項(xiàng)目（20181487）